TriSalus Life Sciences (NASDAQ:TLSI) Upgraded to Strong-Buy at Northland Capmk

by · The Markets Daily

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) was upgraded by equities research analysts at Northland Capmk to a “strong-buy” rating in a report issued on Friday, Zacks.com reports.

Several other analysts have also weighed in on the company. Northland Securities initiated coverage on TriSalus Life Sciences in a report on Friday. They issued an “outperform” rating and a $12.50 price objective for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $12.00 target price on shares of TriSalus Life Sciences in a research report on Thursday, June 27th. Finally, Oppenheimer assumed coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an “outperform” rating and a $10.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $12.50.

Check Out Our Latest Analysis on TriSalus Life Sciences

TriSalus Life Sciences Trading Down 1.0 %

TLSI stock opened at $4.07 on Friday. The firm has a 50 day simple moving average of $4.74 and a 200-day simple moving average of $6.43. The company has a market capitalization of $119.29 million, a P/E ratio of -1.63 and a beta of 0.47. TriSalus Life Sciences has a twelve month low of $3.32 and a twelve month high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The business had revenue of $7.36 million for the quarter. On average, research analysts predict that TriSalus Life Sciences will post -1.53 EPS for the current year.

Insider Buying and Selling at TriSalus Life Sciences

In related news, CEO Mary T. Szela purchased 7,520 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $5.20 per share, for a total transaction of $39,104.00. Following the transaction, the chief executive officer now owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 32.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC bought a new stake in TriSalus Life Sciences in the second quarter valued at $240,000. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth about $1,184,000. Finally, Duquesne Family Office LLC increased its holdings in shares of TriSalus Life Sciences by 35.1% in the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares during the period. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

See Also